Description
GS-9973 is an imidazopyrazine inhibitor of Syk that is currently in clinical trials as a potential treatment for chronic lymphocytic leukemia (CLL). GS-9973 exhibits anticancer chemotherapeutic activity. In vitro, this compound decreases survival of CLL cells, inhibits cell growth, and disrupts chemokine signaling.